1 active not recruiting, 1 completed, 1 enrolling by invitation, 1 terminated. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Enrolling by invitation 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow High-risk Myelodysplastic Syndrome: new trials by email Literature Review of High-risk Myelodysplastic Syndrome trials Research Report on High-risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Bemcentinib - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 2 | Completed | GWT-TUD GmbH | 45 | 2018-12-20 | 2021-12-21 |
Leukemia, Myeloid, Acute (5) · Myelodysplastic Syndromes (2) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasm Metastasis (1) · Recurrence (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Leukemia (5) · Leukemia, Myeloid (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Bone Marrow Diseases (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplastic Processes (1)
Azacitidine (1) · Busulfan (1) · CPX-351 (1) · Cytarabine (1) · Thiotepa (1) · bemcentinib (1) · fludarabine (1) · fludarabine phosphate (1) · ruxolitinib (1)
Ryvu Therapeutics SA (2) · Ascentage Pharma Group Inc. (1) · GWT-TUD GmbH (1) · University of Birmingham (1)
France (3) · Poland (2) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)
Charles Craddock, Professor (1) · Uwe Platzbecker, Prof. (1) · Yifan Zhai, MD, PhD (1)
2025 (1)